Results 131 to 140 of about 4,829 (180)
Pericarditis and Cardiac Tamponade in Patients Treated with First and Second Generation Bruton Tyrosine Kinase Inhibitors: An Underappreciated Risk. [PDF]
Erblich T, Manisty C, Gribben J.
europepmc +1 more source
Risk of Invasive Fungal Infections in Patients With Chronic Lymphocytic Leukemia Treated With Bruton Tyrosine Kinase Inhibitors: A Case-Control Propensity Score-Matched Analysis. [PDF]
Agudelo Higuita NI +8 more
europepmc +1 more source
Efficacy and safety of new-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia/small lymphocytic lymphoma: a systematic review and meta-analysis. [PDF]
Yin S +6 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Resistance to Bruton Tyrosine Kinase Inhibitors
Hematology/Oncology Clinics of North AmericaTargeting Bruton tyrosine kinase (BTK) has revolutionized the therapy for chronic lymphocytic leukemia. As patients remain on therapy, however, resistance develops progressively over time. The most common mechanism of resistance to covalent BTK inhibitors is mutation of the C481 target residue to serine, abrogating covalent binding.
openaire +2 more sources

